Chronic myeloid leukemia (CML) is a clonal bone marrow stem cell neoplasia known to be
responsive to immunotherapy. Despite the success of tyrosine kinase inhibitors (TKIs) …

Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is
effective in many patients, but is not curative and frequently limited by intolerance or …

The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

The management of chronic myeloid leukaemia (CML) has changed extensively over the
past 15 years. Prior to the development of targeted therapies and in the absence of …

Although imatinib is firmly established as an effective therapy for newly diagnosed patients
with chronic myeloid leukemia (CML), the field continues to advance on several fronts. In this …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …